Coxibs were not cost-effective for arthritis pain in patients with average risk for ulcer complications.
نویسنده
چکیده
منابع مشابه
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
BACKGROUND Rofecoxib and celecoxib (coxibs) effectively treat chronic arthritis pain and reduce ulcer complications by 50% compared with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). However, their absolute risk reduction is small and the cost-effectiveness of treatment is uncertain. OBJECTIVE To determine whether the degree of risk reduction in gastrointestinal complications by...
متن کاملReview of the cardiovascular safety of COXIBs compared to NSAIDS
There is no doubt that NSAIDs and COXIBS are the mainstay for managing pain and inflammation in arthritis. Overall, at therapeutically equivalent doses, both NSAIDs and COXIBs provide equivalent analgesic and anti-inflammatory efficacy. However, the gastrointestinal risk associated with NSAIDs is considerable. More recently, the cardiovascular risk associated with NSAIDs and COXIBs has become a...
متن کاملبررسی ارتباط بین افزایش ESR و CRP با درگیری استخوان در عفونت پای دیابتی
Infection is a common complication of diabetic foot that needs hospital admission and surgical intervention.Diabetic foot occurs in one of each ten diabetic patients. Diabetic foot complications are osteomyelitis, arthritis and abscess formation. Radiography, isotope scans, MRI and CT-scan are the procedures that help diagnosis of these complications but these are not always cost effectiv...
متن کاملCardiovascular Effects of COX-2 Inhibitors: A Review of the Literature
When cyclooxygenase-2 (COX-2) inhibitors (coxibs) came on the market, they were expected to provide a treatment alternative to nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) for patients who were at risk for gastrointestinal (GI) complications. For more than five years, coxibs have been prescribed to millions of patients for the treatment of arthritis, acute pain, Alzheimer’s diseas...
متن کاملChannelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.
BACKGROUND Although clinical trial results suggest that meloxicam has less gastrointestinal toxicity than most other non-steroidal anti-inflammatory drugs (NSAIDs), in practice it has been associated with a large number of yellow card reports of gastrointestinal complications. AIMS To estimate whether meloxicam and the coxibs, rofecoxib and celecoxib, have been channelled towards high risk pa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- ACP journal club
دوره 139 2 شماره
صفحات -
تاریخ انتشار 2003